• Home
  • Search
  • MUC4 expression in non-small cell lung cancer.
  • https://doi.org/10.1200/jco.2012.30.15_suppl.e17549Copy DOI Icon

MUC4 expression in non-small cell lung cancer.

Show More
  • Abstract
  • Literature Map
  • Similar Papers
Abstract

e17549 Background: MUC4 has been shown to play a key role in breast and pancreatic cancer. MUC4 expression is seen in the normal bronchial epithelium, but its role in non-small cell lung cancer (NSCLC) is unclear. Here we study the association between MUC4 overexpression and clinical features of NSCLC. Methods: The diagnosis of lung cancer was confirmed in H&E sections. MUC4 level was semi-quantified by immunohistochemistry. Each sample was given a composite score based on intensity and extent of staining. The intensity was graded on a 4 point scale: – (0), + (1), ++ (2), and +++ (3). The extent of staining too was graded on a 4 point scale: 1 (1-25%), 2 (26-50%), 3 (51-75%), and 4 (76-100%). The composite score was obtained by multiplying the two values, with possible scores of 0-12. Poisson mixed effects models were used to compare the score between groups. Kaplan-Meier method was used to estimate survival distributions and the log-rank test was used to compare them. Wilcoxon sign rank test was used to compare the difference in score between lung tissue and corresponding lymph node. P value <0.05 was considered to be statistically significant. Results: 167 samples from 54 non-metastatic NSCLC patients were analyzed. Of these, 13 (25%) patients had stage I, 33 (63%) had stage II and 6 (12%) patients had stage III disease. Distribution of the composite score differed significantly by stage (p=0.0043). A higher proportion of patients with stage I NSCLC had a score of 12 (77%) compared to stage II (18%) and stage III (57%) (p=0.0001). When patients who had data for both the primary tumor and corresponding metastatic lymph node were analyzed, MUC4 expression was higher in the primary tumor compared to the metastasis (p=0.05). The effect of MUC4 expression on survival was analyzed in 29 patients with survival data. Of these, 16 had a composite score of 12, while 13 had a score <12. Patients with a score <12 had significantly worse survival than those with a score of 12 (p<0.045). Conclusions: MUC4 expression is more common in early stage NSCLC and appears to be associated with a better outcome in patients with non-metastatic NSCLC. The therapeutic implications of this finding need to be investigated further.

Similar Papers
  • PDF
  • Research Article
  • Citations6

A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study

  • Sep 27, 2022
  • Clinical & Translational Oncology
  • Dolores Isla +7
  • Research Article
  • Citations73

Venous thromboembolism and nonsmall cell lung cancer

  • Nov 19, 2009
  • Cancer
  • Lisa K Hicks +7
  • Research Article

Predictive Factors for Brain Metastases in Early-Stage Non-Small Cell Lung Cancer

  • Sep 01, 2014
  • 放射治療與腫瘤學
  • Chia-Chun Liang +6
  • Supplementary Content
  • Citations1

Surgical consensus for screening, diagnosis, staging, multimodal management and surveillance of early-stage resectable non-small cell lung cancer (NSCLC) in Malaysia

  • Jul 28, 2025
  • Translational Lung Cancer Research
  • Anand Sachithanandan +8
  • Research Article
  • Citations29

Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer.

  • Jun 01, 2021
  • Lung Cancer: Targets and Therapy
  • Nikhil Shukla +1
  • Research Article
  • Citations19

Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease.

  • Mar 11, 2015
  • Annals of the American Thoracic Society
  • Janaki A Deepak +4
  • PDF
  • Research Article
  • Citations4

Red blood cell distribution width is associated with sarcopenia risk in early-stage non-small cell lung cancer

  • Jan 17, 2024
  • BMC Cancer
  • Qing-Chun Jia +7
  • PDF
  • Research Article
  • Citations9

Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World

  • Jun 29, 2022
  • Frontiers in Oncology
  • Giulia Pasello +11
  • Research Article

Nutritional risk investigation and related factors of 197 patients with early-stage non-small cell lung cancer

  • May 01, 2025
  • Wei sheng yan jiu = Journal of hygiene research
  • Jing Ai +9
  • Research Article
  • Citations44

Adjuvant chemotherapy for surgically resected non–small cell lung cancer

  • Apr 12, 2012
  • The Journal of Thoracic and Cardiovascular Surgery
  • Stephanie Heon +1
  • Research Article
  • Citations7

Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Practical Guide of Current Controversies.

  • May 01, 2025
  • Clinical lung cancer
  • William J Phillips +5
  • Research Article

AB003. Stereotactic body radiation therapy vs. pulmonary resection

  • Sep 01, 2019
  • Shanghai Chest
  • Michael Lanuti
  • Research Article
  • Citations51

Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor–Positive Non–Small Cell Lung Cancer

  • Nov 05, 2021
  • JAMA Network Open
  • Stephanie P L Saw +23
  • Research Article
  • Citations2

Integrated multi-omics landscape of non-small cell lung cancer with distant metastasis.

  • Mar 17, 2025
  • Frontiers in immunology
  • Teng He +7
  • Research Article
  • Citations9

Gemcitabine and cisplatin as neo-adjuvant chemotherapy for non-small cell lung cancer: A phase II study

  • Aug 01, 2007
  • Lung Cancer
  • Adnan Aydiner +9
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.